MOLECULAR GENETIC TESTING IN DIAGNOSTICS OF LUNG CANCER AND OVARIAN CARCINOMA WITH THE USAGE OF CYTOLOGICAL SPECIMENS
- 作者: Grigoruk O.1,2,3, Pupkova E.2, Bazulina L.2, Lazarev A.1,2,3
-
隶属关系:
- Altai Branch of N.N. Blokhin Russian Cancer Research Center
- Altai Regional Oncology Dispensary
- The Altai State Medical University
- 期: 卷 22, 编号 4 (2017)
- 页面: 214-218
- 栏目: Articles
- URL: https://journals.rcsi.science/1028-9984/article/view/40394
- DOI: https://doi.org/10.18821/1028-9984-2017-22-4-214-218
- ID: 40394
如何引用文章
全文:
详细
作者简介
Olga Grigoruk
Altai Branch of N.N. Blokhin Russian Cancer Research Center; Altai Regional Oncology Dispensary; The Altai State Medical University
Email: cytolakod@rambler.ru
MD, PhD, DSc, Head of the Clinical Laboratory Diagnostics Department (for Carrying out Cytological Research Methods) of the Altai Regional Oncological Dispensary; Barnaul, 656049, Russian Federation 656049, Barnaul, Russian Federation; Barnaul, 656049, Russian Federation; Barnaul, 656038, Russian Federation
E. Pupkova
Altai Regional Oncology DispensaryBarnaul, 656049, Russian Federation
L. Bazulina
Altai Regional Oncology DispensaryBarnaul, 656049, Russian Federation
A. Lazarev
Altai Branch of N.N. Blokhin Russian Cancer Research Center; Altai Regional Oncology Dispensary; The Altai State Medical University656049, Barnaul, Russian Federation; Barnaul, 656049, Russian Federation; Barnaul, 656038, Russian Federation
参考
- Злокачественные опухоли. Международный ежеквартальный научно-практический журнал по онкологии. 2015; (4, спец. выпуск): 1-456. doi: 10.18027/2224-5057-2015-4s - 456
- Paez J.G., Jдnne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S. et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004; 304(5676): 1497-500.
- Pao W., Miller V., Zakowski M., Doherty J., Politi K., Sarkaria I. et al. EGF receptor gene mutations are common in lung cancers from «never smokers» and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. USA. 2004; 101(36): 13306-11.
- Mok T.S., Wu Y.L., Thongprasert S., Yang C.H., Chu D.T., Saijo N. et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 2009; 361(10): 947-57. doi: 10.1056/NEJMoa0810699
- Rosell R., Carcereny E., Gervais R., Vergnenegre A., Massuti B., Felip E. et al. Spanish Lung Cancer Group in collaboration with Groupe Franзais de Pneumo-Cancйrologie and Associazione Italiana Oncologia Toracica. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012; 13(3): 239-46. doi: 10.1016/S1470-2045(11)70393-X
- Имянитов Е.Н. Наследственный рак молочной железы. Практическая онкология. 2010; 11(4): 258-66.
- Prat J. Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features. Virchows Arch. 2012; 460(3): 237-49. doi: 10.1007/s00428-012-1203-5
- Kaldawy A., Segev Y., Lavie O., Auslender R., Sopik V., Narod S.A. Low-grade serous ovarian cancer: A review. Gynecol. Oncol. 2016; 143(2): 433-8. doi: 10.1016/j.ygyno.2016.08.320
- Combe P., Chauvenet L., Lefrere-Belda M.A., Blons H., Rousseau C., Oudard S., et al. Sustained response to vemurafenib in a low grade serous ovarian cancer with a BRAF V600E mutation. Invest. New Drugs. 2015; 33(6): 1267-70. doi: 10.1007/s10637-015-0297-4
- Byrski T., Gronwald J., Huzarski T., Grzybowska E., Budryk M., Stawicka M. et al. Pathologic complete response rates in young women with BRCA1-positive breast cancer after neoadjuvantchemotherapy. J. Clin. Oncol. 2010; 28(3): 375-9. doi: 10.1200/JCO.2008.20.7019
- Любченко Л.Н., Батенева Е.И., Абрамов И.С., Емельянова М.А., Будик Ю.А., Тюляндина А.С. и др. Наследственный рак молочной железы и яичников. Злокачественные опухоли. 2013; (2): 53-61. doi: 10.18027/2224-5057-2013-2-53-61
- Демидова И.А. Наследственно обусловленный рак яичников. Современная онкология. 2015; 17(3): 70-5.
- Ledermann J., Harter P., Gourley C., Friedlander M., Vergote I., Rustin G. et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N. Engl. J. Med. 2012;366(15):1382-92. doi: 10.1056/NEJMoa1105535
- Торопова Н.Е., Закамова Е.В., Тетерина Ю.Ю., Козлов С.В., Тимофеева Н.В., Морошкина Г.П. и др. Молекулярно-генетические исследования в практике онкологической клиники. Известия Самарского научного центра РАН. 2015; (2-3): 690-6.
- Consensus for EGFR mutation testing in NSCLC: results of European Workshop. J. Thorac. Oncol. 2010; 5: 1706-13.